---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023839"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:25:57.817893+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Q3 revenue $0.5M, net loss $25.7M; cash $239M covers into H1 2025; 4D-710 CF data positive

## Summary
- Cash, cash equivalents and marketable securities totaled $239M; runway into first half of 2025.
- Revenue $0.5M (down from $1.4M), net loss $25.7M vs $22.2M, R&D $18.9M.
- Interim Phase 1/2 data for 4D-710 CF: no drug-related adverse events, widespread transgene expression in all lung samples.
- Clinical progress highlighted across 4D-150, 4D-310, and 4D-710 programs.

## SEC filing metadata
- accession: 0000950170-22-023839
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017022023839/0000950170-22-023839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017022023839/fdmt-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023839
- JSON: https://secwatch.observer/filing/0000950170-22-023839.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023839.txt

## Key facts
- Earnings Releases
  4D Molecular Therapeutics, Inc. reported the quarter ended September 30, 2022 results: revenue $0.5 million, net income $25.7 million.
  - Period: the quarter ended September 30, 2022
  - Revenue: $0.5 million
  - Net income: $25.7 million
  - Result: reported results
  source text: Revenue: Total revenue for the quarter ended September 30, 2022, was $0.5 million, as compared to $1.4 million for the quarter ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000095017022023839/0000950170-22-023839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.